Harvard Bioscience (HBIO) Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Revenue data on file, last reported at $20.8 million in Q1 2026.

• On a quarterly basis, Revenue fell 4.68% year-over-year to $20.8 million in Q1 2026; TTM through Mar 2026 was $85.5 million, a 6.42% decrease from a year earlier, with the FY2025 full-year figure at $86.6 million, down 8.06% from the prior year.
• Revenue for Q1 2026 stood at $20.8 million, down from $23.7 million in the prior quarter.
• Over the last five years, Revenue for HBIO reached as high as $30.0 million in Q1 2023 and fell as low as $20.4 million in Q2 2025.
• Historically, Revenue has averaged $25.1 million across 5 years, with a median of $24.6 million in 2024.
• Across the five-year window, Revenue climbed 6.63% in 2022 and decreased 19.69% in 2024, its largest moves.
• Year by year, Revenue stood at $28.4 million in 2022, then decreased by 0.96% to $28.2 million in 2023, then declined by 12.78% to $24.6 million in 2024, then declined by 3.34% to $23.7 million in 2025, then retreated by 12.56% to $20.8 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $20.8 million in Q1 2026, $23.7 million in Q4 2025, and $20.6 million in Q3 2025.